EUVIMEDEUVIMED entdecken
Systematische Übersicht

Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategies

Pablo Jiménez-Labaig, Failah Mohamed, Nur Jihan Irwan Tan, Ilves Sanna, Khalid El Bairi, Shah Zeb Khan, Amol Akhade, Teresa Amaral, Dario Trapani, Amol Patel, Kevin J Harrington

European Journal of Cancer · 2025-07 · 225 · 115564

DOI: 10.1016/j.ejca.2025.115564 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Cancer, 2025-07. Verfasst von Pablo Jiménez-Labaig und 10 weiteren Autor:innen. Beteiligte Einrichtung: Head and Neck Unit. The Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, Division of Radiotherapy and Im…. Hauptthemen laut MEDLINE: Neoplasms, Immune Checkpoint Inhibitors, Immunotherapy, B7-H1 Antigen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 91 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Anti-PD-(L)1 inhibitors have transformed cancer treatment. However, their high costs severely restrict their accessibility, especially in low- and middle-income countries (LMIC). Low-dose regimens, inferior to weigh-based or flat dosings, may help address this barrier. Our aim is to evaluate their dosing strategies, clinical outcomes, and potential cost savings. METHODS: WebOfScience, ASCO and ESMO conference databases were systematically searched until January 31st, 2025, for post- commercialization use of anti-PD-(L)1 agents at reduced doses compared to FDA- and/or EMA- approved weight-based regimens. RESULTS: Five clinical trials and 27 observational studies, including 2055 patients, met the review criteria. Two studies had non-inferiority designs, and 26 grouped patients across various treatment lines in the metastatic setting among them. Most studies originated from LMIC (53 %), focusing on head and neck (30 %) and lung cancers (15 %). Low-dose anti-PD-(L)1 use reported radiological responses in 16 (ranging 5-100 %), observing similar responses than pivotal trials in refractory Hodgkin lymphoma, lung and kidney cancers. Risk of bias was serious in 56 % of the studies, while rest was moderate. Nivolumab was the anti-PD-(L)1 most frequently investigated (k = 27). Nivo40mg Q2W (k = 8) and Nivo20mg Q3W (k = 6) were the most assessed doses. More than two-thirds of the studies achieved estimated savings of ≥ 80 % compared to list prices. CONCLUSION: Low-dose anti-PD-(L)1 regimens show promising radiological responses, including as monotherapy, especially in lymphoma, lung and kidney cancers. However, the high risk of bias in available studies limits definitive conclusions. Prudent use may be considered in resource-limited settings. Ongoing non-inferiority trials or near-equivalence are essential to confirm clinical validity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmune Checkpoint InhibitorsImmunotherapyB7-H1 AntigenHealth Services AccessibilityHumans

Stichwörter der Autor:innen

Anti-PD1Anti-PDL1Cost-effectivenessFinancial toxicityICIImmune-checkpoint inhibitorImmunotherapyLow-doseReduced doseUltra-low doseUnderdosing

Substanzen

Immune Checkpoint InhibitorsB7-H1 Antigen

Autor:innen und Institutionen

  • Head and Neck Unit. The Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, Division of Radiotherapy and Imaging, London, United Kingdom; Universitat Autònoma de Barcelona, Barc…
  • Department of Medical Oncology, Cruces University Hospital, Barakaldo, Spain.
  • Head and Neck Unit. The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Faculty of Medical Sciences, UM6P Hospitals, Mohammed VI Polytechnic University, Benguerir 43150, Morocco; National Community Oncology Dispensing Association, Cazenovia, NY 13035, United States.
  • Department of Clinical Oncology, BINOR Cancer Hospital, Bannu, Pakistan.
  • Department of Medical Oncology, Nair Hospital and Topiwala National Medical College Mumbai, Mumbai, India; Suyog Cancer Clinics, Mumbai, India.

Zitieren

APA

Jiménez-Labaig, P., Mohamed, F., Tan, N. J. I., Sanna, I., El Bairi, K., Khan, S. Z., Akhade, A., Amaral, T., Trapani, D., Patel, A., & Harrington, K. J. (2025). Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategies. European Journal of Cancer, 225, 115564. https://doi.org/10.1016/j.ejca.2025.115564

Vancouver

Jiménez-Labaig P, Mohamed F, Tan NJI, Sanna I, El Bairi K, Khan SZ, et al. Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategies. European Journal of Cancer. 2025;225:115564. doi:10.1016/j.ejca.2025.115564

BibTeX
@article{JimnezLabaig2025,
  author = {Jiménez-Labaig, Pablo and Mohamed, Failah and Tan, Nur Jihan Irwan and Sanna, Ilves and El Bairi, Khalid and Khan, Shah Zeb and Akhade, Amol and Amaral, Teresa and Trapani, Dario and Patel, Amol and Harrington, Kevin J},
  title = {Expanding access to cancer immunotherapy: A systematic review of low-dose PD-(L)1 inhibitor strategies},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {225},
  pages = {115564},
  doi = {10.1016/j.ejca.2025.115564}
}
Kostenlos starten →